Skip to Content

SparVax Approval Status

  • FDA approved: No
  • Brand name: SparVax
  • Generic name: recombinant Protective Antigen (rPA) anthrax vaccine
  • Dosage form: Injection
  • Company: PharmAthene, Inc.
  • Treatment for: Anthrax Prophylaxis

SparVax is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection.

Development Status and FDA Approval Process for SparVax

May 26, 2009PharmAthene Submits SparVax Regulatory Strategy to FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.